FDA approves drug for autism irritability

Oct 13, 2006

The U.S. Food and Drug Administration approved Risperdal to treat irritability in autistic children and adolescents.

This is the first time the FDA approved a drug to treat behavior-related problems associated with autism in children, the FDA said in a news release. The drug can be used to treat aggression, deliberate self-injury and temper tantrums, all of which are classified under irritability.

Risperdal is an anti-psychotic drug used to treat adults with schizophrenia, the FDA said. In 2003, it was also approved as a short-term treatment for adults with acute manic episodes or extreme mood swings.

Risperdal is manufactured by Janssen Pharmaceutica N.V. in Beerse, Belgium.

Copyright 2006 by United Press International

Explore further: Flu vaccine may hold key to preventing heart disease

add to favorites email to friend print save as pdf

Related Stories

US company sells out of Ebola toys

3 hours ago

They might look tasteless, but satisfied customers dub them cute and adorable. Ebola-themed toys have proved such a hit that one US-based company has sold out.

UN biodiversity meet commits to double funding

3 hours ago

A UN conference on preserving the earth's dwindling resources wrapped up Friday with governments making a firm commitment to double biodiversity aid to developing countries by 2015.

Partial solar eclipse over the U.S. on Thursday, Oct. 23

4 hours ago

People in most of the continental United States will be in the shadow of the Moon on Thursday afternoon, Oct. 23, as a partial solar eclipse sweeps across the Earth. For people looking through sun-safe filters, from Los Angeles, ...

Recommended for you

Supercomputers link proteins to drug side effects

Oct 20, 2014

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments : 0